VIRBAC CORPORATION NAMES COURTNEY CARNEY DIRECTOR OF MARKETING, PARASITICIDES
Fort Worth, Texas (June 12, 2015) – Virbac Corporation today announced that Mrs. Courtney Carney has been named Director of Marketing, Parasiticides. In this new role, Mrs. Carney will be responsible for planning, directing and providing market leadership for Virbac’s extensive parasiticide franchise in the U.S.
VIRBAC CORPORATION NAMES ROBERT “MAC” MACGREGOR VICE PRESIDENT, INDUSTRIAL OPERATIONS
Fort Worth, Texas (May 18, 2015) – Virbac Corporation today announced that Mr. Robert “Mac” MacGregor has been named Vice President, Industrial Operations, effective immediately. In this role, Mr. MacGregor will be responsible for North American Industrial Operations, encompassing planning, directing and coordinating all manufacturing activities, to efficiently supply customers based upon their needs and pharmaceutical/regulatory requirements.
VIRBAC CORPORATION STRENGTHENS SALES ORGANIZATION
Fort Worth, Texas (April 2, 2015) – Virbac Corporation today announced the promotions of three individuals, Naomi Potts, Bryan Armstrong and Mary Jo McNeily to Sales Director Roles. In these new roles, they will report directly to Jim Van Proosdy, Vice President of Sales for Virbac U.S.
VIRBAC ANNOUNCES THE CLOSING OF THE SENTINEL® BRANDS FAMILY ACQUISITION IN THE U.S.
Fort Worth, Texas (January 5, 2015) – Virbac announces the successful closing, on January 2nd, of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM®, previously marketed by Novartis Animal Health.
VIRBAC ANNOUNCES THAT IT HAS ENTERED INTO AGREEMENT WITH ELI LILLY AND COMPANY
Fort Worth, Texas (October 27, 2014) – Virbac Corporation today announced that it has entered into an agreement with Eli Lilly and Company to acquire major U.S. veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.